Marina Kremyanskaya: PTG-300 Reduces Therapeutic Phlebotomy in Patients with Polycythemia Vera
PTG-300 reversed iron deficiency and eliminated the need for therapeutic phlebotomy in patients with polycythemia vera. Marina Kremyanskaya, MD, PhD, discusses results from the phase...
Lydia Pecker: Hydroxyurea and Diminished Ovarian Reserve in Young Patients with Sickle Cell Anemia
Here, Lydia Pecker, MD, shares findings from a pilot study investigating whether young women with sickle cell anemia have lower antimullerian hormone than age-...
Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia
Treatment with zanubrutinib resulted in a higher combined complete response and very good partial response rate than therapy with ibrutinib in patients with Waldenström...
John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma
Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III...
Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma
Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...
Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma
Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...
Ajay Nooka: Belantamab Mafodotin in Relapsed/Refractory Myeloma
Ajay K. Nooka, MD, shares safety and efficacy data from the phase II DREAMM-6 trial.
Constantine Tam: Zanubrutinib Active in Treatment-Naïve CLL/SLL
Constantine S. Tam, MBBS, MD, discusses findings from the phase III SEQUOIA trial, in which 92% of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma...
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL
Nearly half of patients treated with acalabrutinib plus venetoclax and obinutuzumab achieved a complete response with undetectable minimal residual disease. Benjamin L. Lampson, MD,...
David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.